Skip Navigation

This Article
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Fauser, B. C.J.M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Fauser, B. C.J.M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 13, No. suppl_3, pp. 36-46, 1998
© 1998 European Society of Human Reproduction and Embryology

Developments in human recombinant follicle stimulating hormone technology: are we going in the right direction?

Bart C.J.M. Fauser

Division of Reproductive Medicine, Department of Obstetrics and Gynaecology, Dijkzigt Academic Hospital and Erasmus University Medical School, Rotterdam The Netherlands

Recent developments in recombinant DNA technology have enabled the large scale production of human recombinant follicle stimulating hormone (rFSH); and this compound has recently been introduced to the market. Understanding of the structure–function relationship of FSH isohormones is crucial in understanding discussions on the standardization procedures of gonadotrophin preparations, potential differences in clinical efficacy of the various gonadotrophin preparations and in comprehending future developments (long-acting and short-acting forms, and rFSH preparations with altered isohormone profiles). Differences between immunoreactive and bioactive serum FSH concentrations have been observed following the administration of rFSH. Accordingly, the isohormone distribution of rFSH is similar to, but not identical with, natural human FSH. Issues relevant to daily practice discussed in this review include: the total absence of urinary contaminants allowing for the safe s.c. administration of the compound. Production is independent from urine, and the capacity can be adjusted according to clinical needs. The relationship between serum oestradiol concentrations and number and size of follicles observed by ultrasound may change when rFSH is combined with gonadotrophin-releasing hormone (GnRH) agonist, due to low serum lueinizing hormone (LH) concentrations. In the case of endogenous serum LH concentrations within the normal range, exogenous administration of LH is redundant. In the near future, rFSH preparations with altered bioactivity will be available.

Key words: follicle stimulating hormone/ovarian stimulation/recombinant human gonadotrophins


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.